上海医药利伐沙班片获新加坡药品注册证书

Core Viewpoint - Shanghai Pharmaceuticals announced that its subsidiary, Changzhou Pharmaceutical Factory, received a drug registration certificate from the Health Sciences Authority (HSA) of Singapore for rivaroxaban tablets, allowing the product to be marketed [1] Group 1: Product Approval - Rivaroxaban tablets are approved for reducing the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation, treating and preventing deep vein thrombosis, treating pulmonary embolism, and preventing venous thromboembolism in acutely ill patients [1]